---
title: A Phase 2 Trial of CD24Fc for Prevention of Graft-vs-Host Disease
date: '2023-08-30'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37647633/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20230831181054&v=2.17.9.post6+86293ac
source: Blood
description: Patients who undergo human leukocyte antigen-matched unrelated donor
  (MUD) allogeneic hematopoietic stem cell transplantation (HSCT) with myeloablative
  conditioning for hematologic malignancies often develop acute graft-vs-host disease
  (GVHD) despite standard calcineurin inhibitor-based prophylaxis in combination with
  methotrexate. This trial evaluated a novel human CD24 fusion protein (CD24Fc/MK-7110)
  that selectively targets and mitigates inflammation due to damage-associated ...
disable_comments: true
---
Patients who undergo human leukocyte antigen-matched unrelated donor (MUD) allogeneic hematopoietic stem cell transplantation (HSCT) with myeloablative conditioning for hematologic malignancies often develop acute graft-vs-host disease (GVHD) despite standard calcineurin inhibitor-based prophylaxis in combination with methotrexate. This trial evaluated a novel human CD24 fusion protein (CD24Fc/MK-7110) that selectively targets and mitigates inflammation due to damage-associated ...